These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27835884)

  • 1. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
    Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
    Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in
    Nowak JA; Twombly T; Ma C; Shi Q; Haruki K; Fujiyoshi K; Väyrynen J; Zhao M; Knight J; Mane S; Shergill A; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Tan B; Philip P; O'Reilly EM; Shields AF; Ogino S; Fuchs CS; Meyerhardt JA
    J Clin Oncol; 2024 Aug; 42(24):2853-2859. PubMed ID: 38889377
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    DE Cremoux P; Hamy AS; Lehmann-Che J; Scott V; Sigal B; Mathieu MC; Bertheau P; Guinebretière JM; Pierga JY; Giacchetti S; Brain E; Marty M; Asselain B; Spyratos F; Bièche I
    Anticancer Res; 2018 Mar; 38(3):1485-1490. PubMed ID: 29491076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
    BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
    Ramirez-Ardila DE; Ruigrok-Ritstier K; Helmijr JC; Look MP; van Laere S; Dirix L; Berns EM; Jansen MP
    Mol Oncol; 2016 Oct; 10(8):1363-73. PubMed ID: 27491861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.
    Terán E; Lozano R; Rodríguez CA; Abad M; Figuero L; Muñoz JA; Cigarral B; Rodrígues A; Sancho M; Gómez MA; Morchón D; Montero JC; Sayagués JM; Ludeña MD; Fonseca E
    Cancer Med; 2024 Sep; 13(17):e70101. PubMed ID: 39235099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
    Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
    Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
    Wang L; Chen W; Xie X; He Y; Bai X
    Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
    Moon A; Chin S; Kim HK; Kwak JJ; Koh ES; Kim YW; Jang KT
    Pathology; 2016 Jan; 48(1):35-40. PubMed ID: 27020207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
    Schrage YM; Machado I; Meijer D; Briaire-de Bruijn I; van den Akker BE; Taminiau AH; Kalinski T; Llombart-Bosch A; Bovée JV
    Eur J Cancer; 2010 Feb; 46(3):616-24. PubMed ID: 20004565
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cho YA; Ko SY; Suh YJ; Kim S; Park JH; Park HR; Seo J; Choi HG; Kang HS; Lim H; Park HY; Kwon MJ
    Curr Oncol; 2022 Apr; 29(5):2895-2908. PubMed ID: 35621626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
    Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
    BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.